Reports Q1 revenue $73.46M, consensus $71.26M. Ming Hsieh, chairperson of the board of directors and CEO, said, “I am pleased with the first quarter results and momentum we are seeing so far in 2025. Our Laboratory Services business is well-positioned for growth, and we continue to progress our Therapeutic Development pipeline.”
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FLGT: